Chiaki Terashima-Murase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiaki Terashima-Murase has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Akane Kawamoto
Biological Science Research Laboratories, Kao Corporation, Haga, Tochigi, Japan
1 shared publication - Alan R. Brash
Department of Pharmacology, Vanderbilt University, Nashville, TN, USA
1 shared publication - Almamy Diabaté
Service de dermatologie, CHU de Bouaké, Bouaké, Côte d'Ivoire
1 shared publication - Bamba Vagamon
Department of Dermatology, Université Alassane Ouattara, Service de Dermatologie CHU de Bouaké-Côte d’Ivoire, Bouaké, Côte d’Ivoire
1 shared publication - Daisuke Watanabe
Department of Dermatology Aichi Medical University Aichi Japan
1 shared publication - Hiroyuki Takama
Department of Dermatology, Aichi Medical University, Nagakute, Japan
1 shared publication
Latest Publications
- 6 November 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (5) , 950-952
Case Report: Cutaneous Leishmaniasis—A Hidden Disease in Côte d’Ivoire
: Cutaneous leishmaniasis (CL) is classified as one of the skin-related neglected tropical diseases by the WHO. There have been limited reports of CL in Côte d’Ivoire, with fewer than 20 cases reported from Côte d’Ivoire in the literature since 1967, when it was first identified. Here, we report a case of CL originating in Côte d’Ivoire that we diagnosed during our active case finding activity in the Zounan Hounien District. The patient, a 15-year-old male, presented with multiple noninflammatory skin lesions on the face and trunk that had progressed from nodular to ulcerated lesions over the previous 3 months. Concurrent symptoms included fever, chest pain, cough, and malaise. Investigations for infectious diseases such as HIV and tuberculosis returned negative results. Histopathological analysis of a skin biopsy specimen from the nasal base demonstrated the presence of Leishman-Donovan bodies, confirming a diagnosis of CL. Although treatment with intralesional meglumine antimoniate (Glucantime) injections was intended, the drug could not be administered because the patient unfortunately died shortly after our consultation visit. Because of the rarity of CL in Côte d’Ivoire, awareness remains low, resulting in delayed diagnosis and treatment. Urgent strategies to improve awareness of CL among clinicians practicing in Côte d’Ivoire is required, first to appropriately diagnose and treat CL and second to generate epidemiological data of adequate quality.
- 6 November 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (5) , 950-952
Case Report: Cutaneous Leishmaniasis—A Hidden Disease in Côte d’Ivoire
: Cutaneous leishmaniasis (CL) is classified as one of the skin-related neglected tropical diseases by the WHO. There have been limited reports of CL in Côte d’Ivoire, with fewer than 20 cases reported from Côte d’Ivoire in the literature since 1967, when it was first identified. Here, we report a case of CL originating in Côte d’Ivoire that we diagnosed during our active case finding activity in the Zounan Hounien District. The patient, a 15-year-old male, presented with multiple noninflammatory skin lesions on the face and trunk that had progressed from nodular to ulcerated lesions over the previous 3 months. Concurrent symptoms included fever, chest pain, cough, and malaise. Investigations for infectious diseases such as HIV and tuberculosis returned negative results. Histopathological analysis of a skin biopsy specimen from the nasal base demonstrated the presence of Leishman-Donovan bodies, confirming a diagnosis of CL. Although treatment with intralesional meglumine antimoniate (Glucantime) injections was intended, the drug could not be administered because the patient unfortunately died shortly after our consultation visit. Because of the rarity of CL in Côte d’Ivoire, awareness remains low, resulting in delayed diagnosis and treatment. Urgent strategies to improve awareness of CL among clinicians practicing in Côte d’Ivoire is required, first to appropriately diagnose and treat CL and second to generate epidemiological data of adequate quality.
- 3 February 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 890-903
SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation
The corneocyte lipid envelope, composed of covalently bound ceramides and fatty acids, is important to the integrity of the permeability barrier in the stratum corneum, and its absence is a prime structural defect in various skin diseases associated with defective skin barrier function. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) recently found mutated in ichthyosis. In a patient with SDR9C7 mutation and a mouse Sdr9c7-KO model, we show loss of covalent binding of epidermal ceramides to protein, a structural fault in the barrier. For reasons unresolved, protein binding requires lipoxygenase-catalyzed transformations of linoleic acid (18:2) esterified in ω-O-acylceramides. In Sdr9c7–/– epidermis, quantitative liquid chromatography–mass spectometry (LC-MS) assays revealed almost complete loss of a species of ω-O-acylceramide esterified with linoleate-9,10-trans-epoxy-11E-13-ketone; other acylceramides related to the lipoxygenase pathway were in higher abundance. Recombinant SDR9C7 catalyzed NAD+-dependent dehydrogenation of linoleate 9,10-trans-epoxy-11E-13-alcohol to the corresponding 13-ketone, while ichthyosis mutants were inactive. We propose, therefore, that the critical requirement for lipoxygenases and SDR9C7 is in producing acylceramide containing the 9,10-epoxy-11E-13-ketone, a reactive moiety known for its nonenzymatic coupling to protein. This suggests a mechanism for coupling of ceramide to protein and provides important insights into skin barrier formation and pathogenesis.
- 3 February 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 890-903
SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation
The corneocyte lipid envelope, composed of covalently bound ceramides and fatty acids, is important to the integrity of the permeability barrier in the stratum corneum, and its absence is a prime structural defect in various skin diseases associated with defective skin barrier function. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) recently found mutated in ichthyosis. In a patient with SDR9C7 mutation and a mouse Sdr9c7-KO model, we show loss of covalent binding of epidermal ceramides to protein, a structural fault in the barrier. For reasons unresolved, protein binding requires lipoxygenase-catalyzed transformations of linoleic acid (18:2) esterified in ω-O-acylceramides. In Sdr9c7–/– epidermis, quantitative liquid chromatography–mass spectometry (LC-MS) assays revealed almost complete loss of a species of ω-O-acylceramide esterified with linoleate-9,10-trans-epoxy-11E-13-ketone; other acylceramides related to the lipoxygenase pathway were in higher abundance. Recombinant SDR9C7 catalyzed NAD+-dependent dehydrogenation of linoleate 9,10-trans-epoxy-11E-13-alcohol to the corresponding 13-ketone, while ichthyosis mutants were inactive. We propose, therefore, that the critical requirement for lipoxygenases and SDR9C7 is in producing acylceramide containing the 9,10-epoxy-11E-13-ketone, a reactive moiety known for its nonenzymatic coupling to protein. This suggests a mechanism for coupling of ceramide to protein and provides important insights into skin barrier formation and pathogenesis.